Loading
Fludeoxyglucose F-18 / Computed Tomography / Locally Advanced Lung Neuroendocrine Neoplasm · Phase 2 Trial
ClinicalTrials.gov · August 20, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 clinical trial registry record comparing lutetium Lu 177 dotatate to everolimus in patients with somatostatin receptor-positive advanced bronchial neuroendocrine tumors. The study is currently recruiting and no results have been posted; the primary outcome is median progression-free survival assessed up to 5 years from registration.
Phase 2, Interventional, Randomized, Parallel, Open label, Treatment purpose. Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Ne…; age from 18 Years. Intervention: Arm I (lutetium Lu 177 dotatate). Compared with: Arm II (everolimus) — Active Comparator. n = 70. 29 sites: United States.
This is a Phase 2 clinical trial registry record comparing lutetium Lu 177 dotatate to everolimus in patients with somatostatin receptor-positive advanced bronchial neuroendocrine tumors. The study is currently recruiting and no results have been posted; the primary outcome is median progression-free survival assessed up to 5 years from registration.
This is a registry record with no results posted; no efficacy or safety data are available.
This trial design is appropriate for evaluating a potentially more effective radiopharmaceutical approach versus the standard endocrine therapy. Clinicians should await primary results before altering treatment algorithms; the study will provide evidence on PFS benefit if lutetium Lu 177 dotatate outperforms everolimus in this population.
This is a Phase 2 trial still recruiting with no results posted; it represents early-phase investigation of lutetium Lu 177 dotatate versus everolimus in bronchial neuroendocrine tumors.
As stated by the source record.
Quoted from the source exactly as published.
This trial design is appropriate for evaluating a potentially more effective radiopharmaceutical approach versus the standard endocrine therapy. Clinicians should await primary results before altering treatment algorithms; the study will provide evidence on PFS benefit if lutetium Lu 177 dotatate outperforms everolimus in this population.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT04665739). This is a study registration, not published results. Lead sponsor: National Cancer Institute (NCI). Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 70 participants (ESTIMATED). Conditions: Advanced Lung Neuroendocrine Tumor, Functioning Lung Neuroendocrine Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Tumor G1, Lung Neuroendocrine Tumor G2, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Tumor, Non-Functioning Lung Neuroendocrine Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Tumor. Interventions: PROCEDURE: Biospecimen Collection; PROCEDURE: Computed Tomography; DRUG: Everolimus; OTHER: Fludeoxyglucose F-18; DRUG: Lutetium Lu 177 Dotatate; PROCEDURE: Magnetic Resonance Imaging; PROCEDURE: Positron Emission Tomography; PROCEDURE: Single Photon Emission Computed Tomography; OTHER: Survey Administration. Primary outcome measures: Median progression-free survival (PFS) , From randomization until either radiographic progression confirmed by central radiology review or death, assessed up to 5 years from study registration. Brief summary: This phase II trial studies the effect of lutetium Lu 177 dotatate compared to the usual treatment (everolimus) in treating patients with somatostatin receptor positive bronchial neuroendocrine tumors that have spread to other places in the body (advanced). Lutetium Lu 177-dotate is a radioactive drug. It binds to a protein called somatostatin receptor, which is found on some neuroendocrine tumor cells. Lutetium Lu 177-dotatate builds up in these cells and gives off radiation that may kill them. It is a type of radioconjugate and a type of somatostatin analog. Lutetium Lu 177 dotatate may be more effective than everolimus in shrinking or stabilizing advanced bronchial neuroendocrine tumors.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.